Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06167265 · ClinicalTrials.gov registry record · Phase 1
BE Study of Once Daily PMR Compared to Twice Daily Cilostazol Tablets in Healthy Volunteers
A Phase 1 study, sponsored by Genovate Biotechnology Co., Ltd.,.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT06167265 is a Phase 1 study that has completed, run by Genovate Biotechnology Co., Ltd.,. The registered enrollment target is 40 participants.
The verdict
NCT06167265, a Phase 1 study, has completed, sponsored by Genovate Biotechnology Co., Ltd.,.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The study is designed to evaluate the bioequivalence and the within-subject variability between the test formulation of extended-release tablet of cilostazol (PMR) administered once daily and the reference formulation of immediate- release tablet of cilostazol (Cilostazol) administered twice-daily in normal healthy male and female subjects under fasting conditions.
Interventions
- DRUG Cilostazol Tablet 100 mg
- DRUG PMR Tablet 145 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-11-28 |
| Est. Completion | 2024-01-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06167265
The ClinicalTrials.gov registry entry for NCT06167265 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genovate Biotechnology Co., Ltd.,, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cilostazol Tablet 100 mg is the first listed.
NCT06167265 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06167265 about?
NCT06167265 is a clinical study titled "BE Study of Once Daily PMR Compared to Twice Daily Cilostazol Tablets in Healthy Volunteers". The study is designed to evaluate the bioequivalence and the within-subject variability between the test formulation of extended-release tablet of cilostazol (PMR) administered once daily and the reference formulation of immediate- release tablet of cilostazol (Cilostazol) administered twice-daily i...
What is the current status of trial NCT06167265?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2023-11-28. Estimated completion is 2024-01-18.
What interventions are being tested in trial NCT06167265?
The interventions under investigation include: Cilostazol Tablet 100 mg (DRUG), PMR Tablet 145 mg (DRUG).
Who is sponsoring clinical trial NCT06167265?
This trial is sponsored by Genovate Biotechnology Co., Ltd.,, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.